New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
07:29 EDTISISIsis Pharmaceuticals price target lowered to $55 from $63 at Stifel
Stifel cut its price target on ISIS after updated P2 ISIS-SMNRx data in Type-1 spinal muscular atrophy showed two patients in the trial experienced an event. The firm is not surprised by this development but believes it reinforces the risk of conducting such trials. Stifel keeps a Buy rating on the shares.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
05:26 EDTISISIsis receives orphan status for myotonic dystrophy drug treatment
Subscribe for More Information
January 14, 2015
07:05 EDTISISIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use